Results 51 to 60 of about 34,211 (250)

Mesoporous‐Shell Monolayer Plasmonic Architecture Enables Quantitative and Decision‐Guided SERS

Advanced Science, EarlyView.
Mesoporous‐shell‐regulated molecular transport combined with monolayer hotspot determinism transforms surface‐enhanced Raman spectroscopy (SERS) from ultrasensitive detection into quantitative and decision‐guided molecular sensing. ABSTRACT Quantitative surface‐enhanced Raman spectroscopy (SERS) has long been impeded by stochastic hotspot formation ...
Guangyao Huang, Ying Wang, Yue Fang, Jingyuan Shao, Sensen Hao, Mancun Zhao, Yuan Yao, Junping Wang, Wei Zhou, Hongzhi Wang   +9 more
wiley   +1 more source

Can pharmacogenetics impact the therapeutic effect of cytarabine and anthracyclines in adult acute myeloid leukaemia patients?: A Serbian experience [PDF]

Journal of Medical Biochemistry
Background: Cytarabine-anthracycline-based induction chemotherapy remains the standard of care for remission induction among patients with newly diagnosed acute myeloid leukaemia (AML).
Pravdić Zlatko, Suvajdžić-Vuković Nada, Virijević Marijana, Mitrović Mirjana, Pantić Nikola, Sabljić Nikica, Pavlović Đorđe, Marjanović Irena, Bukumirić Zoran, Vidović Ana, Jaković Ljubomir, Pavlović Sonja, Gašić Vladimir   +12 more
doaj   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

Advanced Science, EarlyView.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu, Chenguang Liu, Weihong Zheng, Xiaofei Tong, Zhengwei Gui, Zonghong Lu, Sun Ieong, Lin Zhang   +7 more
wiley   +1 more source

Ultrasound‐Activated Nanoinhibitors Blocking the Chemo‐Immune Checkpoint to Overcome Chemotherapy‐Induced Immune Resistance

Advanced Science, EarlyView.
A sono‐responsive chemo‐immune checkpoint nanoinhibitor (Sono‐TT8) co‐delivering TPZ chemotherapy and siXkr8 simultaneously kills tumor cells and blocks PS externalization, reversing chemotherapy‐induced immunosuppression and enhancing antitumor immunity. ABSTRACT Breast cancer features an immunosuppressive tumor microenvironment following chemotherapy
Yunfan Liu, Chier Du, Leilei Zhu, Hongjin An, Shengzhe Hou, Yi Lan, Xuemei Tang, Min Xu, Peng Luo, Hua Teng, Hao Yang, Xun Guo, Jianli Ren, Zhiyi Zhou   +13 more
wiley   +1 more source

Role of liposomal anthracyclines in breast cancer

, 2007
Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly ...
Lorusso V., Silvestris N., Manzione L.
core   +1 more source

Mitochondria‐Targeted Nanotherapeutics: A Promising Strategy in Modulating Mitochondrial Function, Transfer, and Transplantation

Advanced Science, EarlyView.
This review summarizes the pathogenic role of mitochondria in diseases and highlights mitochondrial transfer and transplantation as emerging therapeutic strategies. It systematically discusses how nanomaterials are engineered to facilitate these processes, and critically examines the current challenges and future perspectives for their clinical ...
Yuanyuan Su, Zhiyan Gong, Jiao Mu, Lili Huang, Pengfei Yang, Chenli Zhang, Lingshan Zhao, Liling Yang, Jun Deng, Xiaohui Liao   +9 more
wiley   +1 more source

Сhanges in Blood Pressure in Patients with Breast Cancer during Polychemotherapy with Anthracyclines

Львівський клінічний вісник
Introduction. Elevated blood pressure (BP) during treatment with anthracyclines, which include doxorubicin and epirubicin, may be a factor in polychemotherapy (PCT)-related cardiotoxicity, which necessitates monitoring and adjustment of BP in these ...
Світлана Бусел, Олена Волошина, Мар'яна Абрагамович, Ольга Кузнецова, Світлана Алієва   +4 more
doaj   +1 more source

Prognostic value of humoral markers in patients with anthracycline-related cardiac dysfunction

Бюллетень сибирской медицины, 2023
Aim. To carry out a 12-month study on the prognostic role of humoral markers responsible for the main mechanisms of initiation of cardiotoxic myocardial damage (endothelin-1, soluble Fas-L, N-terminal pro-brain natriuretic peptide (NT-proBNP), tumor ...
E. V. Grakova, K. V. Kopeva, S. N. Shilov, E. T. Bobyleva, E. N. Berezikova, V. V. Kalyuzhin, A. T. Teplyakov   +6 more
doaj   +1 more source

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

, 2014
One of the most important adverse effects of anthracyclines is cardiotoxicity. A well-informed decision on the use of anthracyclines in the treatment of childhood cancers should be based on evidence regarding both antitumour efficacy and cardiotoxicity ...
Martine F Raphaël, Huib N Caron, Leontien CM Kremer, Raphaël, Martine F., Caron, Huib N., Kremer, Leontien C. M., Elvira C van Dalen, van Dalen, Elvira C.   +7 more
core   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source